International Journal of Biochemistry Research & Review, ISSN: 2231-086X,Vol.: 16, Issue.: 1
Circulating Survivin and TIMP-1 in Hepatitis C Virus Associated Liver Fibrosis
Bakheet E. M. Elsadek1*, Ahmed A. Abdel Ghany1, Soad M. Abdel Ghany2, Shamardan E. S. Bazeed3, Mohamed A. Abdel Aziz1 and Salama R. Abdel Raheim4
1Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
2Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Egypt.
3Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, South Valley University, Qena, Egypt.
4Department of Biochemistry, Faculty of Medicine, Minia University, Egypt.
Aims: The present study was conducted to assess the clinical utility of survivin, an anti-apoptotic protein, and the profibrogenic tissue inhibitor metalloproteinase-1 (TIMP-1) as non-invasive biomarkers for the discrimination between stages of HCV-associated liver fibrosis that are largely asymptomatic.
Methodology: Circulating survivin and TIMP-1 levels as well as their corresponding proteins and genes expressions were, respectively, assessed by ELISA, Western blot and RT-PCR in 100 HCV-infected patients at different stages of liver fibrosis in comparison to healthy controls.
Results: With the progression of hepatic fibrosis, each of circulating survivin and TIMP-1 as well as their ratio (survivin/TIMP-1) showed a stepwise increase and exhibited significant positive correlations with the fibrotic stage (r=0.98 & p=0.002, r=0.95 & p=0.01, and r=0.93 & p=0.013 respectively). A gradual increase in both survivin and TIMP-1 genes expression was also observed.
Conclusion: In conclusion, survivin, TIMP-1, and their ratio could represent promising biomarkers for prediction and discrimination of different stages of HCV-associated liver fibrosis. The higher sensitivity and specificity of survivin may provide new insights into its possible use as a target for the antifibrotic drugs. Further studies with validated tests on a large scale prospective clinical trial are required to ascertain these results.
urvivin; tissue inhibitor of metalloproteinase-1; liver fibrosis; hepatitis C virus.
Full Article - PDF
DOI : 10.9734/IJBCRR/2017/31609